Introduction {#Sec1}
============

*Staphylococcus aureus* is a facultative pathogen that can cause myriad infectious diseases in humans and animals (Fluit [@CR17]; Foster [@CR18]; Lai et al. [@CR30]; Tong et al. [@CR49]), including endometritis, a common reproductive disease (Sheldon and Owens [@CR44]), and severely impaired reproductive performance (Gilbert et al. [@CR19]); if not controlled, it may promote the development of septicemia and sepsis (Skovbakke and Franzyk [@CR46]). It is estimated that 340 million women get bacterial infections in the uteri each year, and 15\~20% animals develop clinical or subclinical endometritis beyond 3 weeks post-partum, costing billion dollars for treatments annually (Turner et al. [@CR51]). In this study, our focus is mainly on breeding animals, such as cows and sows, which are more susceptible to pathogenic infections under intensive cultivation pressure. Antibiotics are widely used in the clinical prevention and treatment of endometritis, which has increased the emergence of antibiotic-resistant bacteria, especially multi-drug resistant (MDR) bacteria (Eslami et al. [@CR16]). It has been found that *S. aureus* is resistant to tetracycline (43.5%), penicillin (81%), erythromycin (44.5%), clindamycin (51.2%), and ciprofloxacin (30%) (Wu et al. [@CR59]). Meanwhile, the traditional screening of new antibacterial has suffered a considerable decline (da Cunha et al. [@CR13]). This not only affects the treatment options but also may endanger public health (Coyne et al. [@CR11]; Coyne et al. [@CR12]). In recent years, antimicrobial peptides (AMPs) have attached attention of scientists by their properties such as broad-spectrum antimicrobial activity and non- or low resistance of bacteria.

Among AMPs, insect defensins (with 32--52 residues) are a large group of evolutionarily conserved cationic, cysteine-rich peptides and display a broad-spectrum activity against bacteria, fungi, and virus. They share a cysteine-stabilized αβ motif (CSαβ), which has been proved to be a valuable structural template for the development of novel antimicrobials (Koehbach [@CR29]). However, natural insect defensins often have low activity and some toxicity toward mammalian cells, which limit their therapeutic application (Barreto-Santamaria et al. [@CR5]). Therefore, some engineered peptides were designed based on the CSαβ scaffold, such as tenecin 1, Def-AcAA, and NZ2114, and they exhibited improved antibacterial activity and reduced cytotoxicity (Ahn et al. [@CR1]; Landon et al. [@CR31]; Zhang et al. [@CR65]). Although, many attempts have been made on the medical application of AMPs, few of them have been introduced into the market yet (Kang et al. [@CR26]; Yi et al. [@CR61]). The screening and testing of effective AMPs (or designer AMPs) for therapeutic applications are ongoing in the pharmaceutical industry (Andersson et al. [@CR3]).

In our previous study, a designed CSαβ peptide ID13 from DLP4 showed enhanced activity (MIC 0.95\~1.91 μM), reduced hemolysis, and cytotoxicity toward mouse macrophages RAW 264.7 (Li et al. [@CR32]). In the present study, effects of ID13 on bacterial membrane and gene expression of *S. aureus* CVCC 546 were explored, and its in vitro and in vivo therapeutic efficacies were evaluated through AMP-antibiotic synergism, intracellular antimicrobial action, lipoteichoic acid (LTA) neutralization, and mouse endometritis model.

Materials and methods {#Sec2}
=====================

Strains, cell lines, and reagents {#Sec3}
---------------------------------

The bacterial strains *Staphylococcus epidermidis* ATCC 12228 and *Escherichia coli* ATCC 25922 were purchased from American Type Culture Collection (ATCC). *S. aureus* CVCC 546, *Streptococcus pneumoniae* CVCC 2350, *Streptococcus suis* CVCC 3928, *Salmonella pullorum* CVCC 533, and *Salmonella Enteritidis* CVCC 3377 were purchased from the China Veterinary Culture Collection Center (CVCC). Mouse macrophages RAW 264.7 and endometrial epithelial cells (MEECs) were obtained from Peking Union Medical College and iCell Bioscience Inc. (Shanghai, China), respectively. LTA and 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) were purchased from Sigma-Aldrich (China). Antibiotics used in the study were purchased from Meilun Biotech Co., Ltd (Dalian, China). Peptides ID13 and DLP4 were expressed and purified in our lab as previously described (Li et al. [@CR32]), with the purity of 91.2% and 92%, respectively. Other reagents were of analytical grade.

Bioavailability of peptides {#Sec4}
---------------------------

### Antimicrobial activity {#Sec5}

The antimicrobial activity of peptides was calculated by minimal inhibitory concentration (MIC) via microtiter plate assay as previously depicted (Wiegand et al. [@CR58]). Each test was conducted in triplicate.

### Peptide stability in biological fluids {#Sec6}

The stability of peptide ID13 in simulated gastric fluid (SGF), simulated intestinal fluid (SIF), and mouse serum was carried out as previously described (Benincasa et al. [@CR7]; Liu et al. [@CR35]; Yu et al. [@CR63]). Simply, a final concentration of 100-μg/mL ID13 was prepared with SGF, SIF, or 25% serum and incubated at 37 °C. At different time intervals, an aliquot of 30-μL ID13 mix was taken and tested against *S. aureus* CVCC 546 by drop diffusion assay (Cerovsky et al. [@CR10]). ID13 (100 μg/mL) prepared with PBS was used as a positive control; SGF, SIF, and 25% serum were used as negative controls. The agar plates were incubated overnight at 37 °C, and inhibition zones were determined.

Anti-*S. aureus* activity of ID13 at different pH {#Sec7}
-------------------------------------------------

The antimicrobial activity of ID13 (100 μg/mL) in different pH buffers (pH 2.0, 4.0, 6.0, 8.0, and 10.0) was tested (Yu et al. [@CR63]). After incubated with different pH buffers at 37 °C for 3 h, 30-μL ID13 and corresponding controls were dropped on Mueller-Hinton agar (MHA) plate and incubated overnight at 37 °C for anti-*S. aureus* activity determination.

Mammalian cytotoxicity {#Sec8}
----------------------

The effect of peptides on MEECs' viability was evaluated by using the MTT assay as depicted before (Wang et al. [@CR56]).

Effects of ID13 on *S. aureus* membrane and gene expression {#Sec9}
-----------------------------------------------------------

### Membrane depolarization {#Sec10}

Membrane depolarization was carried out as depicted previously with some slight modifications (Kindmark et al. [@CR27]; Yang et al. [@CR60]). *S. aureus* CVCC 546 cells at 10^8^ CFU/mL were treated with peptides at 1 ×, 2 ×, or 4 ×MIC. After incubation at 37 °C for 2 h, the bacteria were washed twice with PBS buffer and resuspended. A final concentration of 1-μM Rhodamine 123 (Rh123) was added. The cells without peptide treatment were set as negative control. After incubation at 37 °C for 30 min, Rh123 fluorescence from the cytoplasm was detected by flow cytometry.

### Transcriptome sequencing {#Sec11}

*S. aureus* CVCC 546 at 2.5 × 10^8^ CFU/mL was inoculated into 250-mL Erlenmeyer flasks. The cultures were supplemented with peptide ID13 at subinhibitory concentration (4 μg/mL) at 37 °C for 60 min. RNA extraction was then performed using an RNeasy mini kit (Qiagen). The RNAs from three biological replicates were pooled; library preparation and RNA sequencing (RNA-seq) were conducted in Novogene (Beijing, China). Bioinformatic analysis was carried out using the CLC Genomics Workbench. Primary sequencing reads were mapped to the reference transcriptome and genome of *S. aureus* TW20 (GenBank accession number FN433596). The abundances of transcripts were generated in fragments per kilobase of transcript sequence per million base pairs sequenced (FPKM) (Trapnell et al. [@CR50]). Differential expression analysis was assessed with an R package, where \|log~2~ (fold change)\| \> 1 and *q* value \< 0.005 were used as screening criteria for differential genes (Wang et al. [@CR54]). For function and pathway analysis, we used the GOseq software (Young et al. [@CR62]) and KEGG database (<http://www.genome.jp/kegg/>). The raw sequence data are publicly accessible at <https://bigd.big.ac.cn/gsa/browse/CRA002331>.

Efficacies of peptide ID13 in vitro {#Sec12}
-----------------------------------

### ID13-antibiotic synergism {#Sec13}

Combinatory interactions of ID13 and antibiotics were tested by using the checkerboard titration method as described previously (Zhang et al. [@CR65]).

### Intracellular antimicrobial activity {#Sec14}

*S. aureus* can internalize into host cells to avoid being killed by traditional antibiotics (Wang et al. [@CR55]). To explore the intracellular antimicrobial activity of ID13, MEECs prepared in DMEM free of antibiotics were dispensed in 12-well plates at 2.5 × 10^5^ cells/mL and 750 μL/well. After 24-h incubation, an equal volume of *S. aureus* CVCC 546 at 2.5 × 10^7^ CFU/mL was supplemented and coincubated with MEECs for 0.5 h. Then, 50 μg/mL of lysostaphin was added and incubated for 1 h to kill extracellular bacteria. After washing with PBS, the MEECs were treated with different concentrations of peptides or vancomycin for 24 h and processed for colony counting (Di Grazia et al. [@CR15]).

### LTA neutralization {#Sec15}

The anti-inflammatory activity of peptide ID13 was analyzed as depicted previously with some modifications (Liu et al. [@CR35]; Skovbakke and Franzyk [@CR46]). The mouse macrophages RAW 264.7 were resuspended in DMEM to a density of 1 × 10^6^ cells/mL; an aliquot of 500 μL/well was seeded in 24-well plates for 24-h incubation. A final concentration of 10-μg/mL LTA was then added and incubated for another 3 h. After washing with PBS, cells were treated with peptides at different concentrations. Cells treated with DLP4 and vancomycin or ones untreated were used as positive and negative controls. The supernatants were harvested and analyzed for cytokine levels of TNF-α, IL-1ß, IL-6, and IL-10 using an enzyme-linked immunosorbent assay (ELISA) kit (R&D systems, USA). Each group was made in triplicate.

Efficacies of peptide ID13 in mice endometritis model {#Sec16}
-----------------------------------------------------

The animal procedures were approved by the Institutional Animal Care and Use Committee of Chinese Academy of Agricultural Sciences (CAAS). Animal studies were performed with female CD-1 mice, weight 25 g. Sixty mice were randomly divided into six groups (*n* = 10). To induce endometritis, 100-μL *S. aureus* CVCC 546 (1 × 10^8^ CFU/mL) was injected into the uteri of mice via vagina for 3 days with a 1-mL syringe. Twenty-four hours post-infection, mice were administered intraperitoneally (i.p.) with peptides at 5, 10, or 15 mg/kg once daily for 3 days. Mice raised without any treatment, treated with vancomycin, or treated with PBS were used as the blank, positive, and negative controls, respectively. At 24 h post-treatment, peripheral blood and the uterine tissues were collected from the mice. Peripheral blood (*n* = 5) from the negative and blank control was used for white blood cell analysis; the others (*n* = 5) from each group were centrifuged; and the serum was used for TNF-α, IL-1ß, IL-6, and IL-10 analysis by using the ELISA kit (R&D systems, USA). Uteri (*n* = 5) from each group were homogenized; the homogenate was diluted with a 1: 10 (w/v) ratio and dropped on Baird-Parke (BP) agar plate for pathogenic bacteria isolation and identification. Segments from another five uteri in each group were fixed in 4% paraformaldehyde for histopathological analyses by hematoxylin-eosin (H&E) staining; the rest ones were extracted for TLR2 and NF-κB pathway analysis by western blot (Li et al. [@CR33]).

Statistical analysis {#Sec17}
--------------------

All data were analyzed with GraphPad Prism 7 and presented as mean ± standard deviation (SD), where "*n*" represents the number of animals or samples. Comparisons between groups were performed by one-way analysis of variance (ANOVA) followed by Dunnett's multiple test. *p* \< 0.05 was considered statistically significant.

Results {#Sec18}
=======

Bioavailability of peptide ID13 {#Sec19}
-------------------------------

### Antimicrobial activity {#Sec20}

As shown in Table [1](#Tab1){ref-type="table"}, the activity of ID13 with MICs of 0.95\~1.91 μM was higher than that of its parent peptide DLP4 with MICs of 3.75\~14.99 μM against *S. aureus* CVCC 546, *S. epidermidis* ATCC 12228, *S. pneumoniae* CVCC 2350, and *S. suis* CVCC 3928, respectively. However, similar to DLP4, ID13 had no activity against Gram-negative bacteria (MIC \> 30.5 μM).Table 1Antibacterial activity of peptides against pathogenic strains.PeptidesMICs (μM)*S. aureus* CVCC 546*S. epidermidis* ATCC 12228*S. pneumonia* CVCC 2350*S. suis* CVCC 3928*E. coli* ATCC 25922*S. pullorum* CVCC 533*S. Enteritidis* CVCC 3377ID130.951.910.950.95\>30.50\>30.50\>30.50DLP43.7514.997.503.75\>29.98\>29.98\>29.98Van^a^0.670.670.340.1786.1586.1586.15^a^Vancomycin

### Stability of peptide ID13 in biological fluids {#Sec21}

Proteases in the gastrointestinal tract and blood limit the use of AMPs (da Cunha et al. [@CR13]; Yu et al. [@CR63]). The susceptibility of peptide ID13 to pepsin, trypsin, and serum was detected by using the drop diffusion method. After treatment with SGF or 25% serum for 60 min, peptide ID13 retained 90.79% or 99.54% activity against *S. aureus* CVCC 546, respectively, while it has easily undergone proteolysis in less than 5 min in SIF (Fig. [1a](#Fig1){ref-type="fig"}).Fig. 1Bioavailability of peptide ID13. **a** The stability of peptide ID13 in simulated gastric fluid (SGF), simulated intestinal fluid (SIF), serum, and **b** different pH buffers. NC, negative control; PC, positive control; ST, stability tested of peptide ID13 prepared in biological fluids. c Cytotoxicity of peptides ID13, DLP4, and vancomycin (Van) toward MEECs (*n* = 4)

The varying pH buffers (2.0 to 10.0) had no effect on ID13 activity (\> 99%) against *S. aureus* CVCC 546 (Fig. [1b](#Fig1){ref-type="fig"}). These results indicate that ID13 can be used via oral administration.

### Cytotoxicity of peptides toward MEECs {#Sec22}

The cell viability of ID13 toward MEECs was 89.62% at a concentration of 256 μg/mL, which was nearly equal with that of vancomycin (90.15%), and showed lower cytotoxicity than that of DLP4 (74.14%) at 256 μg/mL, indicating a low cytotoxicity (Fig. [1c](#Fig1){ref-type="fig"}).

Effects of peptide ID13 on *S. aureus* CVCC 546 {#Sec23}
-----------------------------------------------

### ID13-depolarized *S. aureus* CVCC 546 membrane {#Sec24}

As shown in Fig. [2a](#Fig2){ref-type="fig"}, when *S. aureus* CVCC 546 cells were treated with peptide ID13 at 1 ×, 2 ×, or 4 × MIC for 2 h, the fluorescence intensity of Rh 123 was reduced by 23.54%, 26.49%, and 23.05%, respectively. There was no significant concentration relationship of ID13. Comparably, the fluorescence intensity from cells treated with 1 ×, 2 ×, or 4 × MIC vancomycin was dose-dependently increased by 23.1%, 26.6%, and 32.3%, respectively. The membrane depolarization by ID13 correlates with the findings of the transcriptional analyses as follows.Fig. 2The effects of peptide ID13 on *S. aureus*. **a** The membrane depolarization, **b** differential gene expression, **c** enriched GO terms, and **d** KEGG pathway of ID13-treated *S. aureus* CVCC 546

#### ID13 regulated *S. aureus* CVCC 546 gene expression {#FPar1}

To investigate the effects of ID13 on gene expression of *S. aureus*, transcriptome sequencing was performed. A total of 640 differentially expressed genes (DEGs) were identified, including 266 upregulated genes and 374 downregulated genes (Fig. [2b](#Fig2){ref-type="fig"}). Significant changes in response to ID13 are involved in the genes that are essential to metabolic processes and pathways such as membrane function, biosynthesis of primary and secondary metabolites, and microbial metabolism in diverse environments (Fig. [2c--d](#Fig2){ref-type="fig"}), which play an important role in cell viability and pathogenicity.

### Membrane potential (ΔΨ)-related genes {#Sec25}

ΔΨ is crucial to energy metabolism and is maintained by the transmembrane gradients of ions (Na^+^, K^+^, Cl^−^, and H^+^, etc.), which reflects the state of the bacterial physiology. A decline of ΔΨ will result in the inhibition of energy metabolism (Shapiro [@CR43]; van der Stel et al. [@CR52]).

As shown in Supplementary Table [S1](#MOESM1){ref-type="media"}, the genes (*mnhABCDEHF*, *fabD*, *lytM*, *ureF*, and *ipdC*) encoding ion binding and transport proteins were reduced by 1.1- and 3.2-fold, while the other ones (*ebh*, *mtlA*, *sdrC*, *sdrD*, *sdrE*, *copA*, *hutG*, and *zinT*) were upregulated. The decreased expression of *mnhABCDEHF*, specifically responsible for Na^+^/H^+^ antiporter, suggested a decline of ΔΨ and energy biosynthesis (Castro et al. [@CR9]). The genes (*nreB*, *ftnA*, *narGHT*, *nasD*, *pflAB*, *adh1*, *ldhAB*, and *natA*) for energy metabolism were upregulated (1.3 to 7.8-fold), while *trxAB* (encoding thioredoxin and thioredoxin reductase) (Villanueva et al. [@CR53]), *glpD* (encoding glycerol-3-phosphate dehydrogenase) (Szalus-Jordanow et al. [@CR48]), *fda* (encoding fructose-bisphosphate aldolase class 1) (Capodagli et al. [@CR8]), *pgk* (encoding phosphoglycerate kinase) (Liew et al. [@CR34]), and *eno* (encoding enolase) (Dai et al. [@CR14]) were downregulated. The results indicated that ID13 might negatively affect the endergonic processes such as ATP synthesis through *mnhABCDEHF* inhibition.

### Pathogenicity-related genes {#Sec26}

*S. aureus* causes host infections through surface colonization, entry, and invasion process (Bayer et al. [@CR6]). Colonization is mediated by the microbial surface component recognizing adhesive matrix molecules (MSCRAMMs), mainly encoded by *clfB*, *fnbA*, *eno*, *ebh*, *spa*, *agrABC*, and *sdrCDE* (Speziale et al. [@CR47]), which are under control of *sar* and *agr*, and *agr* is also partly regulated by *sar* (Azara et al. [@CR4]; Speziale et al. [@CR47]). The extracellular DNA is important in the course of biofilm formation, and it is regulated by *cid* and *lrg* operon, which induces and inhibits cell lysis, respectively (Rice et al. [@CR40]; Sadykov and Bayles [@CR42]; Shen et al. [@CR45]). Meanwhile, LytSR system regulates the expression of *lrg*; disruption of the *lytSR* genes induces increased autolysis (Sadykov and Bayles [@CR42]). In addition, the genes *secA* (encoding a key component of the general bacterial secretion system required for toxins secretion), *hly* (encoding hemolysin), and *cap* (encoding capsular polysaccharide) also play various roles in bacterial evasion of the host immune defense (Jin et al. [@CR25]; Weidenmaier and Lee [@CR57]; Zhang and Austin [@CR64]).

As shown in Supplementary Table [S2](#MOESM1){ref-type="media"}, the transcript levels of *clfB*, *ebh*, *spa*, *agrABC*, and *sdrCDE* but not *fnbA* and *eno* were elevated 1.8 to 6.2 fold. It showed that ID13 exhibited positive effect on the expression of most MSCRAMM-encoding genes. Meanwhile, the expression of positive regulatory genes of MSCRAMMs (*agrABC* and *sarS*) was also upregulated (1.8 to 3.2- fold). The transcript levels of the positive regulator of autolysis *cidA* remarkably decreased by 4.2 fold, while the expression of negative regulator *lrgB* increased by 2.5 fold. It indicated that *S. aureus* might protect itself from being induced autolysis by ID13. Due to the increased expression of *secA* for toxin secretion, *hly* expression was also elevated. Compared with the control, ID13-treated *S. aureus* significantly downregulated the levels of genes (*capABCDGLMN*) for biofilm formation. These results suggested that ID13 affected *S. aureus* biofilm formation by inhibiting capsule polysaccharide synthesis, thereby reducing bacterial pathogenicity.

Efficacies of peptide ID13 in vitro {#Sec27}
-----------------------------------

### Synergism of peptide ID13 with antibiotics {#Sec28}

The combination of antimicrobial peptides with antibiotics is an efficacious strategy to combat antibiotic resistance of bacteria (Zharkova et al. [@CR67]). As shown in Fig. [3a](#Fig3){ref-type="fig"}, the FICI values for ID13 and vancomycin (Van), ampicillin (Amp), rifampin (Rif), or ciprofloxacin (Cip) ranged from 0.1875 to 0.375, indicating the synergistic effect. It demonstrated that the combined application of peptide ID13 with antibiotics has a potential to be used to inhibit the growth of *S. aureus* CVCC 546.Fig. 3In vitro efficacy of peptide ID13. **a** Combined application of peptide ID13 with antibiotics against *S. aureus* CVCC 546, vancomycin, ampicillin, rifampin, and ciprofloxacin that are represented by Van, Amp, Rif, and Cip, respectively, and **b** antimicrobial activity against intracellular *S. aureus* CVCC 546. Inhibition of LTA-induced cytokines **c** TNF-α, **d** IL-1β, **e** IL-6, and **f** IL-10 from RAW 264.7. Statistical significance of differences between experimental and LTA groups were determined using the one-way ANOVA and Dunnett's multiple comparison. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001

### Intracellular antimicrobial activity {#Sec29}

As shown in Fig. [3b](#Fig3){ref-type="fig"}, ID13, DLP4, and vancomycin could enter MEEC cells and kill over 99% of *S. aureus* CVCC 546 in a dose-dependent manner. The killing rate of 200-μg/mL ID13 and DLP4 was up to 99.92% and 99.90%, slightly lower than that of vancomycin (99.99%). This result demonstrated that ID13 exhibited remarkable bactericidal efficiency against intracellular *S. aureus*.

### Anti-inflammatory activity {#Sec30}

As shown in Fig. [3c--f](#Fig3){ref-type="fig"}, LTA could stimulate the production of TNF-α, IL-1β, IL-6, and IL-10 in RAW 264.7. After treatment with ID13, DLP4, and vancomycin, the pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 decreased in a concentration-dependent manner in all tests. After incubation with 50-μg/mL ID13, the levels of cytokines TNF-α (1648.57 ± 209.29 pg/mL), IL-6 (203.9 ± 8.65 pg/mL), and IL-1β (215.17 ± 19.54 pg/mL) were reduced by 68.18%, 70.61%, and 70.44%, higher than those of DLP4. In contrast, after treatment with 25-μg/mL ID13, anti-inflammatory cytokine IL-10 was increased by 7.47%, lower than that of DLP4 (45.09%) and vancomycin (81.26%). The results suggest that ID13 has the ability to suppress pro-inflammatory responses in macrophages.

Efficacy of peptide ID13 in vivo {#Sec31}
--------------------------------

Given its low cytotoxicity and stability in SGF, SIF, serum, and different pH buffers, the in vivo therapeutic potential of peptide ID13 was further investigated through an endometritis model of mouse.

### Morphology changes in the mice uterus {#Sec32}

By anatomy, the uterus showed normal morphology and had no adhesion with the surrounding tissues in the blank control; comparatively, in the negative control, the uterus appeared abnormal, including enlarged uterine volume; dilated and tortuous lumen; thinned uterine wall; yellow pus or clear liquid in the lumen; and swollen, congested, and dark red perimetrium surface (Supplementary Fig. [S1](#MOESM1){ref-type="media"}).

### Leukocytes and pathogens analysis {#Sec33}

In the negative and blank controls, it was observed significant changes in the white blood cells (Supplementary Table [S3](#MOESM1){ref-type="media"}). The number of white blood cells (14.56 ± 3.00 10^9^ cells/L), neutrophils (9.65 ± 2.00 10^9^ cells/L), and lymphocytes (3.25 ± 0.83 10^9^ cells/L) in the negative control was significantly higher than those in the blank control. The percentage of neutrophils was increased remarkably by 66.24 ± 1.51%, while that of lymphocytes was decreased significantly by 22.24 ± 2.33%. The result indicated that endometritis can be established in mice by intrauterine inoculation of *S. aureus* CVCC 546.

To isolate and identify *S. aureus* CVCC 546, homogenized uterine samples diluted 1:10 (w/v) in PBS were dropped on BP agar supplemented with potassium tellurite yolk enrichment broth, and then the isolates were further conformed through 16S rRNA gene sequence analysis. As shown in Supplementary Fig. [S2](#MOESM1){ref-type="media"}a, *S. aureus* CVCC 546 isolates were found to be the major bacterial pathogen isolated from uteri of mouse; after amplicon and molecular identification (Supplementary Fig. [S2](#MOESM1){ref-type="media"}b), 16S rRNA gene sequence BLAST on NCBI website (<https://blast.ncbi.nlm.nih.gov/Blast.cgi>) showed that the isolated pathogen was most similar to *S. aureus* according to taxonomy report (Supplementary Fig. [S2](#MOESM1){ref-type="media"}c).

### Ameliorating pathological uteri {#Sec34}

Histopathological analysis of uteri by H&E staining showed no histological abnormality that was found in the blank control with normal endometrium, myometrium, and perimetrium (Fig. [4a](#Fig4){ref-type="fig"}). Comparatively, structures of the uteri in the negative control were obviously destroyed; the glands of the endometrium were atrophied and even disappeared; a large number of inflammatory cells (mainly neutrophils and lymphocytes, accompanied by a small number of monocytes) were observed in the stroma of the endometrium as well as fibrous tissue hyperplasia. In addition, inflammation also caused the shedding of epithelial cells into uterine cavity (Fig. [4b](#Fig4){ref-type="fig"}). These results showed that the endometritis model of mouse was successfully established by infection of *S. aureus* CVCC 546.Fig. 4Histopathological analysis of uteri by H&E staining (× 200). Histopathology of uteri of the **a** blank, **b** negative (PBS), **c** positive (vancomycin, 10 mg/kg) control, and (**d**--**f**) groups treated with 5, 10, and 15 mg/kg peptide ID13, respectively. Red arrow, gland; yellow arrow, neutrophils; cyan arrow, lymphocytes; green arrow, the shedding of epithelial cells into uterine cavity

After administration of ID13 (5, 10, or 15 mg/kg), pathological conditions were improved rapidly in a dose-dependent manner (Fig. [4d--f](#Fig4){ref-type="fig"}). Only a small amount of scattered inflammatory cells were observed in part of uterus after treatment with 10-mg/kg vancomycin or 15-mg/kg peptide ID13 (Fig. [4](#Fig4){ref-type="fig"} c and f). The results suggested that similar to vancomycin, ID13 could ameliorate the pathological outcome of mouse uteri infected with *S. aureus* CVCC 546.

### Attenuating inflammatory cytokines {#Sec35}

As shown in Fig. [5](#Fig5){ref-type="fig"}, the production of inflammatory cytokines TNF-α, IL-1β, IL-6, and IL-10 in the negative control (PBS) was remarkably increased in serum from mice infected with *S. aureus* CVCC 546. After treatment with ID13, the levels of inflammatory cytokines TNF-α, IL-1β, IL-6, and IL-10 significantly decreased in a dose-dependent manner. Administration with 15-μg/mL ID13 resulted in a reduction of cytokines TNF-α (107.80 pg/mL), IL-6 (163.14 pg/mL), IL-1β (218.64 pg/mL), and IL-10 (55.48 pg/mL), which was roughly equivalent to 10 μg/mL vancomycin (TNF-α, 124.92 pg/mL; IL-6, 134.74 pg/mL; IL-1β, 198.72 pg/mL; IL-10, 48.20 pg/mL).Fig. 5Effects of ID13 on inflammatory cytokines **a** TNF-α, **b** IL-1β, **c** IL-6, and **d** IL-10 in serum from mice (*n* = 5). Statistical significance of differences between experimental and negative control (PBS) was determined using the one-way ANOVA and Dunnett's multiple comparison. \*\**p* \< 0.01, \*\*\**p* \< 0.001, \*\*\*\**p* \< 0.0001.

### Regulating NF-κB signaling pathway {#Sec36}

TLR2 is critical for the host immune cells and can recognize microbe-associated pathogenic molecules (e.g., LTA), which stimulates the production of inflammatory cytokines and results in the activation of NF-κB signaling pathway (Goldstein [@CR22]). To explore the anti-inflammatory mechanism of peptide ID13, the expression of TLR2 and NF-κB was analyzed by western blot. As shown in Fig. [6](#Fig6){ref-type="fig"}, the relative content of TLR2 in the negative control (PBS) was significantly higher than that in the blank control (CK). ID13 could reduce the TLR2, IκB, p-IκB, p65, and p-p65 contents in a dose-dependent manner. However, the levels of p-IκB and p-p65 were lower than those of IκB and p65, indicating a negative regulation by ID13. These results suggested that ID13 inhibited the expression of TLR2 and downregulated NF-κB signaling pathway.Fig. 6Effects of peptide ID13 on TLR2-NF-κB signaling (*n* = 5). Statistical significance of differences between experimental and negative control (PBS) was determined using the one-way ANOVA and Dunnett's multiple comparison. \**p* \< 0.05, \*\**p* \< 0.01, \*\*\**p* \< 0.001

Discussion {#Sec37}
==========

*S. aureus* is a common pathogen that can cause post-partum clinical and subclinical endometritis in humans and animals (Turner et al. [@CR51]; Zhang et al. [@CR66]). During the long-term use of antibiotics, *S. aureus* has been found to develop resistance (Hiramatsu [@CR23]; Lai et al. [@CR30]; Pirolo et al. [@CR38]). To combat antibiotic-resistant *S. aureus*, insect defensins are promising candidates for the development of novel antimicrobials (Koehbach [@CR29]). In this study, the efficacies of a designed peptide ID13 from insect defensin DLP4 were assessed against *S. aureus* CVCC 546 in vitro and in vivo.

Antimicrobial activity, stability, and cytotoxicity are important factors in the preliminary screening of candidate peptides. ID13 displayed potent antimicrobial activity (MICs 0.95\~1.91 μM) against Gram-positive bacteria (Table [1](#Tab1){ref-type="table"}); high stability in SGF (90.79%), serum (99.54%), and different pH buffers (\> 99%); and lower cytotoxicity (89.62% viability) toward MEECs than its parent peptide DLP4 (74.14% viability) (Fig. [1](#Fig1){ref-type="fig"}), which may be attributed to its increased hydrophobicity, decreased charge, and shorter amino acid side chain (Li et al. [@CR32]). These results also suggested a good bioavailability for ID13.

Structure analysis showed that ID13 is an amphipathic, cationic, and CSαβ peptide (Li et al. [@CR32]), indicating the high affinity to anionic bacterial membranes, which was exactly confirmed in membrane depolarization of ID13 (Fig. [2a](#Fig2){ref-type="fig"}). Membrane potential is maintained by a substantial proportion of the energy and electron (Kinkel et al. [@CR28]); depolarization of membrane disrupts the energy generation and electron transfer, which is specifically reflected in the depression of Na(+)/H(+) pump activity (Supplementary Table [S1](#MOESM1){ref-type="media"}) (Castro et al. [@CR9]). The cationic antimicrobial peptide (Temporin L-NH~2~, ovispirin-1-NH~2~, and dermaseptin K4-S4 (1-16)-NH~2~)-treated *S. aureus* showed a downregulation of *nar*, *nas*, and *adh1*(Pietiainen et al. [@CR37]), which were increased in ID13-treated *S. aureus* in our study (Supplementary Table [S1](#MOESM1){ref-type="media"}). *cap* is responsible for capsular polysaccharide expression (Gill et al. [@CR20]) and plays an important role in biofilms formation (Prokopovich and Perni [@CR39]); a significant downregulation of *cap* expression (Supplementary Table [S2](#MOESM1){ref-type="media"}) implies a reduced bacterial infection (Weidenmaier and Lee [@CR57]).

*S. aureus* can internalize into host cells to form an intracellular pathogen pool, thereby avoiding being killed by traditional antibiotics and causing further damages (Al Kindi et al. [@CR2]; Wang et al. [@CR55]). Meanwhile, the bacterial cell wall component LTA is an important immunostimulatory virulence factor in *S. aureus* infections (Ginsburg [@CR21]), can activate pro-inflammatory signaling (Rockel and Hartung [@CR41]), and promotes the development of sepsis (Hotchkiss and Karl [@CR24]). NZ2114, a variant of the fungus-derived defensin plectasin from *Pseudoplectania nigrella*, is a CSαβ peptide, which could be internalized into the cells via clathrin-mediated endocytosis and macropinocytosis, and distributed in the cytoplasm. It exhibits intracellular bacteriostatic efficacy with the reduction of *S. aureus* colony counting (Wang et al. [@CR56]). ID13 shares the same structure with NZ2114 and thus may have a similar mechanism of cell internalization to kill intercellular *S. aureus* like NZ2114 does. In present study, almost all of the intracellular *S. aureus* CVCC 546 were killed by ID13 (99.92%), slightly lower than that of vancomycin (99.99%) (Fig. [3b](#Fig3){ref-type="fig"}). In recent years, many peptides such as Temporins A, NZ2114, and LL-37 have been proved to exhibit a high efficiency against intracellular *S. aureus* in host cells (Di Grazia et al. [@CR15]; Noore et al. [@CR36]; Wang et al. [@CR56]). Moreover, ID13 could inhibit the production of inflammation cytokines in RAW 246.7 and in mice challenged with LTA or *S. aureus* CVCC 546 (Figs. [3c--e](#Fig3){ref-type="fig"} and [5a--c](#Fig5){ref-type="fig"}). However, the level of IL-10 decreased in mice (Fig. [5d](#Fig5){ref-type="fig"}) might attribute to the effects of different kind of immune cells induced by LTA and *S. aureus* CVCC 546 in vitro and in vivo, respectively. Also, ID13 could attenuate the phosphorylation of NF-κB in mice (Fig. [6](#Fig6){ref-type="fig"}), thereby downregulating the expression of downstream pro-inflammatory cytokines (Fig. [5a--c](#Fig5){ref-type="fig"}). These results suggested that ID13 can improve the pathological conditions of mouse endometritis (Fig. [4c--f](#Fig4){ref-type="fig"}).

In conclusion, peptide ID13 exhibited stable antimicrobial activity in SGF and serum against *S. aureus* CVCC 546 and lower cytotoxicity than its parent peptide DLP4. ID13 caused a depolarization of bacterial membrane and downregulated the expression of genes involved in membrane potential maintenance and biofilm formation. ID13 had a synergistic effect with ancient antibiotics and intracellular antimicrobial activity of *S. aureus* CVCC 546 in MEECs. ID13 improved pathological conditions of endometritis of mouse induced by *S. aureus* and inhibited the production of TNF-α, IL-1ß, IL-6, and IL-10. Furthermore, TLR2-NF-κB signaling pathway was significantly suppressed by ID13. These results suggest that ID13 could be a potential antimicrobial for clinical application.
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